Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP2K1 | Q02750 | 18/20 | 0.55 |
| ▸ | MAP2K2 | P36507 | 4/20 | 0.55 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.55 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.55 |
| ▸ | PRKAG1 | P54619 | 1/20 | 0.55 |
| ▸ | ADCK1 | Q86TW2 | 1/20 | 0.55 |
| ▸ | PRKAG2 | Q9UGJ0 | 1/20 | 0.55 |
| ▸ | CA2 | P00918 | 3/20 | 0.41 |
| ▸ | PIM1 | P11309 | 1/20 | 0.36 |
| ▸ | CAMK2B | Q13554 | 1/20 | 0.36 |
| ▸ | FLT1 | P17948 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12807998 | 0.93 | MAP2K1 (0.47) | MAP2K1MAP2K2CHEK1MAPK10PRKAG1 | |
| SCHEMBL10254216 | 0.89 | MAP2K1 (0.42) | MAP2K1MAP2K2CHEK1MAPK10PRKAG1 | |
| SCHEMBL389984 | 0.81 | MAP2K1 (0.62) | MAP2K1MAP2K2CHEK1MAPK10PRKAG1 | |
| SCHEMBL345633 | 0.80 | MAP2K1 (0.71) | MAP2K1MAP2K2CHEK1MAPK10PRKAG1 | |
| SCHEMBL685422 | 0.77 | MAP2K1 (0.61) | MAP2K1MAP2K2CHEK1MAPK10PRKAG1 | |
| SCHEMBL12869983 | 0.77 | MAP2K1 (0.61) | MAP2K1MAP2K2CHEK1MAPK10PRKAG1 | |
| SCHEMBL13941493 | 0.76 | MAP2K1 (0.81) | MAP2K1MAP2K2CHEK1MAPK10PRKAG1 | |
| SCHEMBL14127547 | 0.75 | MAP2K1 (0.69) | MAP2K1MAP2K2CHEK1MAPK10PRKAG1 | |
| SCHEMBL387871 | 0.75 | MAP2K1 (0.58) | MAP2K1MAP2K2CHEK1MAPK10PRKAG1 | |
| SCHEMBL391748 | 0.74 | MAP2K1 (0.79) | MAP2K1MAP2K2CHEK1MAPK10PRKAG1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8101799-B2 | Derivatives of N-(arylamino) sulfonamides as inhibitors of MEK | ARDEA BIOSCIENCES (US) | 2012-01-24 | — | — | US | disclosed |
| US-8101799-B2 | Derivatives of N-(arylamino) sulfonamides as inhibitors of MEK | ARDEA BIOSCIENCES (US) | 2012-01-24 | — | — | US | disclosed |
| US-20080058340-A1 | MEK kinase (mitogen-activated ERK-activating kinases or MAP kinase kinase); cancer, tumors, infections, autoimmune disorders, stroke, ischemia, rheumatoid arthritis, multiple sclerosis, psoriasis, restenosis; 1-sulfonamido-2-(phenylamino)-4-fluorobenzene compounds | ARDEA BIOSCIENCES, INC. (US) | 2008-03-06 | — | — | US | disclosed |
| US-20080058340-A1 | MEK kinase (mitogen-activated ERK-activating kinases or MAP kinase kinase); cancer, tumors, infections, autoimmune disorders, stroke, ischemia, rheumatoid arthritis, multiple sclerosis, psoriasis, restenosis; 1-sulfonamido-2-(phenylamino)-4-fluorobenzene compounds | ARDEA BIOSCIENCES, INC. (US) | 2008-03-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080058340-A1 | MEK kinase (mitogen-activated ERK-activating kinases or MAP kinase kinase); cancer, tumors, infections, autoimmune disorders, stroke, ischemia, rheumatoid arthritis, multiple sclerosis, psoriasis, restenosis; 1-sulfonamido-2-(phenylamino)-4-fluorobenzene compounds | BRAF, MAPK1, MAPK12 | MAP2K1 32/4885MAP2K2 23/4885CHEK1 391/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.